Oman Pharmaceuticals and Healthcare Report

 Published On: Feb, 2014 |    No of Pages: 102 |  Published By: BMI Pharmaceuticals and Healthcare | Format: PDF
Request Free Sample   Share on Whatsapp

View: This quarter has seen a focus on development and opening of government-funded and privatehealthcare infrastructure projects aimed at meeting growing domestic demand for healthcare services andpositioning the country as a regional medical tourism hub. While the country boasts a number of attractionsto gauge foreign drugmakers' interest, we continue to highlight that Oman's small population and limitedper capita spending limits pharmaceutical market growth.
Headline Expenditure Projections
- Pharmaceuticals: OMR175mn (US$455mn) in 2013 to OMR191mn (US$503mn) in 2014; 9.3% in localcurrency terms and 10.7% in US dollar terms. Forecast broadly in line with Q114.
- Healthcare: OMR785mn (US$2.04bn) in 2013 to OMR852mn (US$2.24bn) in 2014; +8.6% in localcurrency terms and +10.0 in US dollar terms. Forecast broadly in line with Q114.

Industry View 7
SWOT 10
Political 12
Economic 13
Business Environment 14
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Oman Pharmaceutical Sales, Historical Data And Forecasts, 2010-2018 16
Healthcare Market Forecast 17
Table: Oman Healthcare Expenditure Trends, Historical Data and Forecasts, 2010-2018 18
Table: Oman Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 18
Table: Oman Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 19
Prescription Drug Market Forecast 20
Table: Oman Prescription Drug Market Indicators, Historical Data And Forecasts, 2010-2018 21
Patented Drug Market Forecast 22
Table: Oman Patented Drug Market Indicators, Historical Data And Forecasts 2010 - 2018 23
Generic Drug Market Forecast 24
Table: Oman Generic Drug Market Indicators, Historical Data And Forecasts, 2010-2018 25
OTC Medicine Market Forecast 25
Table: Oman Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts, 2010-2018 26
Pharmaceutical Trade Forecast 27
Table: Oman Pharmaceutical Trade Data And Forecasts (US$mn), 2010-2018 28
Table: Oman Pharmaceutical Trade Data And Forecasts (OMRmn), 2010-2018 28
Other Healthcare Data 29
Key Risks To BMI's Forecast Scenario 30
Macroeconomic Forecasts 31
Economic Analysis 31
Table: Oman - Sectors' Contribution To Overall Gdp, Current Prices 32
Table: Oman - Gas Prices For Industrial Consumers 36
Table: Oman - Economic Activity 40
Industry Risk Reward Ratings 41
Middle East And Africa Risk/Reward Ratings 41
Oman Risk/Reward Ratings 49
Rewards 49
Risks 50
Market Overview 51
Industry Trends And Developments 52
Industry Trends And Developments 52
Epidemiology 52
Communicable Diseases 52
Non-Communicable Diseases 53
Healthcare Sector 54
Public Healthcare Sector Developments 56
Private Healthcare Sector Developments 57
Table: Number Of Health Centres In Oman By Region 59
Table: Number And Type Of Health Institutions In Oman In 2011 60
Healthcare Insurance 60
Telemedicine 61
Medical Tourism 62
Research And Development 63
Clinical Trials 65
Regulatory Development 66
Regulatory Developments 67
Intellectual Property Regime 67
Regional Harmonisation 68
Pricing And Reimbursement Regime 69
Competitive Landscape 73
Domestic Pharmaceutical Industry 73
Foreign Pharmaceutical Industry 74
Pharmaceutical Distribution 75
Company Profile 76
Zynova/Oman Pharmaceutical Products Company 76
National Pharmaceutical Industries (NPI) 79
Novartis 82
GlaxoSmithKline 85
Sanofi 87
Johnson & Johnson 89
Demographic Forecast 91
Demographic Outlook 91
Table: Oman's Population By Age Group, 1990-2020 ('000) 92
Table: Oman's Population By Age Group, 1990-2020 (% of total) 93
Table: Oman's Key Population Ratios, 1990-2020 94
Table: Oman's Rural And Urban Population, 1990-2020 94
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Ratings Methodology 99
Ratings Overview 100
Table: Pharmaceutical Risk/Reward Ratings Indicators 100
Indicator Weightings 101

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.